Harmine augments electrically evoked dopamine efflux in the nucleus accumbens shell

Journal of Psychopharmacology

Volumn 27, Issue 1, 2013, Pages 98-108

  Brierley, Daniel I ^a   Davidson, Colin ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

5 HT2A receptor; ayahuasca; cocaine; dopamine; Harmine; ketanserin; moclobemide; monoamine oxidase; nucleus accumbens; voltammetry

Indexed keywords

COCAINE; DOPAMINE; HARMINE; KETANSERIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; BRAIN SLICE; CONTROLLED STUDY; CYCLIC POTENTIOMETRY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; EVOKED CORTICAL RESPONSE; MALE; MOLECULAR MECHANICS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN; COCAINE; COCAINE-RELATED DISORDERS; DOPAMINE; DOPAMINE AGONISTS; HARMINE; KETANSERIN; MALE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; NUCLEUS ACCUMBENS; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN;

EID: 84871603534     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112463125     Document Type: Article

References (70)

1. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther. 2007 ; 113: 296-320
2. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 ; 408: 297-315
3. Barrot M, Calza L, Pozza M, et al. Differential calbindin- immunoreactivity in dopamine neurons projecting to the rat striatal complex. Eur J Neurosci. 2000 ; 12: 4578-4582
4. Barrot M, Olivier JD, Perrotti LI, et al. CREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuli. Proc Natl Acad Sci U S A. 2002 ; 99: 11435-11440
5. Benoit-Marand M, Borrelli E, Gonon F. Inhibition of dopamine release via presynaptic D2 receptors: time course and functional characteristics in vivo. J Neurosci. 2001 ; 21: 9134-9141
6. BonHomme N, De Deurwaerdere P, Le Moal M, et al. Evidence for 5-HT4 receptor substype involvement in the enhancement of striatal dopamine release induced by serotonin: a microdialysis study in the halothane-anesthetized rat. Neuropharmacol. 1995 ; 34: 269-279
7. Brierley D, Davidson C. Developments in harmine pharmacology - implications for ayahuasca use and drug-dependence treatment. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012 ;:
8. Budygin EA, John CE, Mateo Y, et al. Lack of cocaine effect on dopamine clearance in the core and shell of the nucleus accumbens of dopamine transporter knock-out mice. J Neurosci. 2002 ; 22: RC222
9. Callaway JC, McKenna DJ, Grob CS, et al. Pharmacokinetics of hoasca alkaloids in healthy humans. J Ethnopharmacol. 1999 ; 65: 243-256
10. Campbell BM, Walker PD. MK-801 prevents dopamine D1 but not serotonin 2A stimulation of striatal preprotachykinin mRNA expression. Neuroreport. 2001 ; 12: 953-955
11. Cappendijk SL, Fekkes D, van Dalen A, et al. The acute effects of norharman on cocaine self-administration and sensorimotor function in male Wistar rats. Eur Neuropsychopharmacol. 2001 ; 11: 233-239
12. Chen A, Hough CJ, Li H. Serotonin type II receptor activation facilitates synaptic plasticity via N-methyl-D-aspartate-mediated mechanism in the rat basolateral amygdala. Neuroscience. 2003 ; 119: 53-63
13. Chen BT, Hopf FW, Bonci A. Synaptic plasticity in the mesolimbic system: therapeutic implications for substance abuse. Ann N Y Acad Sci. 2010 ; 1187: 129-139
14. Clemett DA, Punhani T, Duxon MS, et al. Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacol. 2000 ; 39: 123-132
15. Cuny GD, Ulyanova NP, Patnaik D, et al. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors. Bioorg Med Chem Lett. 2012 ; 22: 2015-2019
16. Darchen F, Scherman D, Laduron PM, et al. Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Mol Pharmacol. 1988 ; 33: 672-677
17. Davidson C, Chauhan NK, Knight S, et al. Modelling ischaemia in vitro: effects of temperature and glucose concentration on dopamine release evoked by oxygen and glucose depletion in a mouse brain slice. J Neurosci Methods. 2011 ; 202: 165-172
18. Davidson C, Ellinwood EH, Douglas SB, et al. Effect of cocaine, nomifensine, GBR 12909 and WIN 35428 on carbon fiber microelectrode sensitivity for voltammetric recording of dopamine. J Neurosci Methods. 2000 ; 101: 75-83
19. De Deurwaerdere P, Navailles S, Berg KA, et al. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci. 2004 ; 24: 3235-3241
20. De Paula DC, Torricelli AS, Lopreato MR, et al. 5-HT(2A) Receptor activation in the dorsolateral septum facilitates inhibitory avoidance in the elevated T-maze. Behav Brain Res. 2012 ; 226: 50-55
21. Di Matteo V, Di Giovanni G, Di Mascio M, et al. Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors. Brain Res. 2000 ; 865: 85-90
22. Drucker G, Raikoff K, Neafsey EJ, et al. Dopamine uptake inhibitory capacities of beta-carboline and 3,4-dihydro-beta-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products. Brain Res. 1990 ; 509: 125-133
23. Fabregas JM, Gonzalez D, Fondevila S, et al. Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend. 2010 ; 111: 257-261
24. Garris PA, Wightman RM. Distinct pharmacological regulation of evoked dopamine efflux in the amygdala and striatum of the rat in vivo. Synapse. 1995 ; 20: 269-279
25. Glennon RA, Dukat M, Grella B, et al. Binding of β -carbolines and related agents at serotonin (5-HT2 and 5-HT1A), dopamine (D2) and benzodiazepine receptors. Drug Alcohol Depend. 2000 ; 60: 121-132
26. Gockler N, Jofre G, Papadopoulos C, et al. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J. 2009 ; 276: 6324-6337
27. Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology. 2004 ; 29: 969-981
28. Greengard P, Valtorta F, Czernik AJ, et al. Synaptic vesicle phosphoproteins and regulation of synaptic function. Science. 1993 ; 259: 780-785
29. Grella B, Dukat M, Young R, et al. Investigation of hallucinogenic and related β -carbolines. Drug Alcohol Depend. 1998 ; 50: 99-107
30. Grob CS, McKenna DJ, Callaway JC, et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis. 1996 ; 184: 86-94
31. Hamsa T, Kuttan G. Studies on anti-metastatic and anti-invasive effects of harmine using highly metastatic murine B16F-10 melanoma cells. J Environ Pathol Toxicol Oncol. 2011 ; 30: 123-137
32. Henry JP, Gasnier G, Isambert MF, et al. Ketanserin as a ligand of the vesicular monoamine transporter. Adv Biosci. 1991 ; 82: 147-150
33. Herraiz T, Gonzalez D, Ancin-Azpilicueta C, et al. Beta-carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol. 2010 ; 48: 839-845
34. Husbands SM, Glennon RA, Gorgerat S, et al. Beta-carboline binding to imidazoline receptors. Drug Alcohol Depend. 2001 ; 64: 203-208
35. Hyland BI, Reynolds JN, Hay J, et al. Firing modes of midbrain dopamine cells in the freely moving rat. Neuroscience. 2002 ; 114: 475-492
36. Iurlo M, Leone G, Schilstrom B, et al. Effects of harmine on dopamine output and metabolism in rat striatum: role of monoamine oxidase-A inhibition. Psychopharmacology (Berl). 2001 ; 159: 98-104
37. Lee TH, Balu R, Davidson C, et al. Differential time-course profiles of dopamine release and uptake changes induced by three dopamine uptake inhibitors. Synapse. 2001 ; 41: 301-310
38. Lee TH, Gee KR, Davidson C, et al. Direct, real-time assessment of dopamine release autoinhibition in the rat caudate-putamen. Neuroscience. 2002 ; 112: 647-654
39. Leiderman DB, Shoptaw S, Montgomery A, et al. Cocaine rapid efficacy screening trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence. Addiction. 2005 ; 100: S1 - S11
40. Leysen JE, Eens A, Gommeren W, et al. Identification of nonserotonergic [3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets: relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs. J Pharmaco Exp Ther. 1988 ; 244: 310-321
41. Li R, Peng N, Li XP, et al. (-)-Epigallocatechin gallate regulates dopamine transporter internalization via protein kinase C-dependent pathway. Brain Res. 2006 ; 1097: 85-89
42. LizarzaburuIJ (2003) Peru seeks tribal cure for addiction. BBC News, 11May2003. Available at: http://news.bbc.co.uk/1/hi/programmes/crossing- continents/3243277.stm.
43. Ma Y, Wink M. The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res. 2010 ; 24: 146-149
44. McKenna DJ, Towers GH, Abbott F. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca. J Ethnopharmacol. 1984 ; 10: 195-223
45. Menequz A, Betto P, Ricciarello G. Different effects of harmine on plasma concentrations of L-DOPA and on cerebral dopamine metabolism in rabbits and rats. Pharmacol. 1994 ; 48: 360-366
46. Meredith GE, Baldo BA, Andrezjewski ME, et al. The structural basis for mapping behavior onto the ventral striatum and its subdivisions. Brain Struct Funct. 2008 ; 213: 17-27
47. Michael DJ, Wightman RM. Electrochemical monitoring of biogenic amine neurotransmission in real time. J Pharm Biomed Anal. 1999 ; 19: 33-46
48. Mijnster MJ, Raimundo AG, Koskuba K, et al. Regional and cellular distribution of serotonin 5-hydroxytryptamine2a receptor mRNA in the nucleus accumbens, olfactory tubercle, and caudate putamen of the rat. J Comp Neurol. 1997 ; 389: 1-11
49. Muller CP, Huston JP. Determining the region-specific contributions of 5-HT receptors to the psychostimulant effects of cocaine. Trends Pharmacol Sci. 2006 ; 27: 105-112
50. Nash JF. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci. 1990 ; 47: 2401-2408
51. Navailles S, De Deurwaerdere P. Presynaptic control of serotonin on striatal dopamine function. Psychopharmacology (Berl). 2011 ; 213: 213-242
52. Navailles S, Moison D, Ryczko D, et al. Region-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin2C receptors. J Neurochem. 2006 ; 99: 1311-1319
53. Owesson CA, Hopwood SE, Callado LF, et al. Altered presynaptic function in monoaminergic neurons of monoamine oxidase-A knockout mice. Eur J Neurosci. 2002 ; 15: 1516-1522
54. Paxinos G, Watson C The Rat Brain in Stereotaxic Coordinates. 1997 ) The Rat Brain in Stereotaxic Coordinates. 3rd ed. New York: Academic Press. New York: Academic Press ; 1997 :
55. Pepper JP, Baumann MH, Ayestas M, et al. Inhibition of MAO-A fails to alter cocaine-induced increases in extracellular dopamine and norepinephrine in rat nucleus accumbens. Brain Res Mol Brain Res. 2001 ; 87: 184-189
56. Phillips PE, Hancock PJ, Stamford JA. Time window of autoreceptor- mediated inhibition of limbic and striatal dopamine release. Synapse. 2002 ; 44: 15-22
57. Pimpinella G, Palmery M. Interaction of beta-carbolines with central dopaminergic transmission in mice: structure-activity relationships. Neurosci Lett. 1995 ; 189: 121-124
58. Rollema H, Wilson GG, Lee TC, et al. Effect of co-administration of varenicline and antidepressants on extracellular monoamine concentrations in rat prefrontal cortex. Neurochem Int. 2011 ; 58: 78-84
59. Rothman RB, Blough BE, Baumann MH. Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction. Exp Clin Psychopharmacol. 2008 ; 16: 458-474
60. Schmitt KC, Reith ME. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann N Y Acad Sci. 2010 ; 1187: 316-340
61. Schwarz MJ, Houghton PJ, Rose S, et al. Activities of extract and constituents of Banisteriopsis caapi relevant to Parkinsonism. Pharmacol Biochem Behav. 2003 ; 75: 627-633
62. Shahinas D, Macmullin G, Benedict C, et al. Harmine is a potent antimalarial targeting Hsp90 and synergizes with chloroquine and artemisinin. Antimicrob Agents Chemother. 2012 ; 56: 4207-4213
63. Sievert MK, Ruoho AE. Peptide mapping of the [125I]iodoazidoketanserin and [125I]2-N-[(3-iodo-4-azidophenyl)propionyl]tetrabenazine binding sites for the synaptic vesiclemonoamine transporter. J Biol Chem. 1997 ; 272: 26049-26055
64. Toner C, Stamford J. 'Real time' measurement of dopamine release in an in vitro model of neostriatal ischaemia. J Neurosci Methods. 1996 ; 67: 133-140
65. Urban JD, Clarke WP, von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol ExpTher. 2007 ; 320: 1-13
66. Venton BJ, Seipel AT, Phillips PE, et al. Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. J Neurosci. 2006 ; 26: 3206-3209
67. Willoughby J, Glover V, Sandler M. Histochemical localisation of monoamine oxidase A and B in rat brain. J Neural Transm. 1988 ; 74: 29-42
68. Yadav PN, Kroeze WK, Farrell MS, et al. Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther. 2011 ; 339: 99-105
69. Yorgason JT, Espana RA, Jones SR. Demon voltammetry and analysis software: analysis of cocaine-induced alterations in dopamine signaling using multiple kinetic measures. J Neurosci Methods. 2011 ; 202: 158-164
70. Zhang L, Doyon WM, Clark JJ, et al. Controls of tonic and phasic dopamine transmission in the dorsal and ventral striatum. Mol Pharmacol. 2009 ; 76: 396-404